このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Bio-Techne 過去の業績
過去 基準チェック /26
Bio-Techneは、平均年間9.5%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間 成長しています。収益は、平均年間14.2% 11.2%収益成長率で 成長しています。 Bio-Techneの自己資本利益率は8.1%であり、純利益率は14.5%です。
主要情報
9.5%
収益成長率
8.7%
EPS成長率
Life Sciences 業界の成長 | 21.5% |
収益成長率 | 11.2% |
株主資本利益率 | 8.1% |
ネット・マージン | 14.5% |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching
Sep 11Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
Aug 24When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16収支内訳
収支内訳
Bio-Techne の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 1,159 | 168 | 429 | 97 |
31 Mar 24 | 1,154 | 203 | 417 | 96 |
31 Dec 23 | 1,145 | 224 | 424 | 93 |
30 Sep 23 | 1,144 | 247 | 406 | 93 |
30 Jun 23 | 1,137 | 285 | 397 | 92 |
31 Mar 23 | 1,124 | 271 | 415 | 92 |
31 Dec 22 | 1,120 | 262 | 390 | 91 |
30 Sep 22 | 1,118 | 292 | 400 | 89 |
30 Jun 22 | 1,106 | 272 | 392 | 87 |
31 Mar 22 | 1,076 | 225 | 361 | 85 |
31 Dec 21 | 1,030 | 210 | 350 | 80 |
30 Sep 21 | 985 | 177 | 334 | 76 |
30 Jun 21 | 931 | 140 | 312 | 71 |
31 Mar 21 | 848 | 184 | 296 | 67 |
31 Dec 20 | 799 | 175 | 282 | 66 |
30 Sep 20 | 760 | 248 | 271 | 65 |
30 Jun 20 | 739 | 229 | 267 | 65 |
31 Mar 20 | 755 | 187 | 273 | 65 |
31 Dec 19 | 745 | 195 | 271 | 64 |
30 Sep 19 | 734 | 93 | 266 | 64 |
30 Jun 19 | 714 | 96 | 262 | 62 |
31 Mar 19 | 703 | 121 | 257 | 60 |
31 Dec 18 | 682 | 96 | 244 | 58 |
30 Sep 18 | 661 | 128 | 232 | 57 |
30 Jun 18 | 643 | 126 | 216 | 55 |
31 Mar 18 | 619 | 112 | 194 | 55 |
31 Dec 17 | 599 | 114 | 187 | 55 |
30 Sep 17 | 577 | 73 | 183 | 54 |
30 Jun 17 | 563 | 76 | 175 | 54 |
31 Mar 17 | 541 | 74 | 170 | 51 |
31 Dec 16 | 528 | 82 | 158 | 49 |
30 Sep 16 | 517 | 101 | 145 | 47 |
30 Jun 16 | 499 | 104 | 138 | 45 |
31 Mar 16 | 482 | 105 | 130 | 44 |
31 Dec 15 | 465 | 99 | 125 | 44 |
30 Sep 15 | 456 | 107 | 121 | 43 |
30 Jun 15 | 452 | 108 | 115 | 41 |
31 Mar 15 | 427 | 108 | 101 | 38 |
31 Dec 14 | 408 | 116 | 86 | 34 |
30 Sep 14 | 380 | 107 | 71 | 32 |
30 Jun 14 | 358 | 111 | 60 | 31 |
31 Mar 14 | 345 | 113 | 54 | 30 |
31 Dec 13 | 330 | 114 | 50 | 30 |
30 Sep 13 | 321 | 114 | 46 | 30 |
質の高い収益: TECHは 高品質の収益 を持っています。
利益率の向上: TECHの現在の純利益率 (14.5%)は、昨年(25.1%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: TECHの収益は過去 5 年間で年間12.9%増加しました。
成長の加速: TECHは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。
収益対業界: TECHは過去 1 年間で収益成長率がマイナス ( -41.1% ) となったため、 Life Sciences業界平均 ( -10.8% ) と比較することが困難です。
株主資本利益率
高いROE: TECHの 自己資本利益率 ( 8.1% ) は 低い とみなされます。